Results 61 to 70 of about 6,798 (212)

Genome Manipulation in Microalgae: A Systematic Map on Improved Traits, Strains, and Their Commercial Applications

open access: yesReviews in Aquaculture, Volume 18, Issue 4, September 2026.
ABSTRACT Microalgae are promising platforms for producing diverse biocompounds relevant to multiple commercial sectors, and the use of genomic technologies in microalgae is rapidly expanding. To examine the research trends, we conducted a bibliographic analysis (systematic map) of this rapidly developing field. Our study presents a descriptive overview
Irene Gallego   +2 more
wiley   +1 more source

Actinomycin Derivatives: Structural Diversification and Biological Activities

open access: yesChemMedChem, Volume 21, Issue 15, 14 August 2026.
Actinomycins are chromopeptide antibiotics exhibiting remarkable structural diversity and broad bioactivity. This review traces their development from naturally occurring D‐, X‐, A‐, G‐, Y‐, and Z‐type analogs to precursor‐directed, synthetic, and semisynthetic derivatives.
Özge Can, Erdal Bedir
wiley   +1 more source

Construction of a recombinant immunotoxin [PDF]

open access: yes, 1995
University of Technology, Sydney. Faculty of Science.In recent years a number of therapeutically useful immunotoxins have been produced using recombinant gene technology.

core   +1 more source

Design of a Humanized Immunotoxin Based on Pertuzumab-Derived scFv and Shiga-Like Toxin 2 Subunit A Against Breast Cancer: An In Silico Study [PDF]

open access: yesJournal of Mazandaran University of Medical Sciences
Background and purpose: Breast cancer is the second cause of mortality among women. HER2, a member of the epidermal growth factor receptor family, is overexpressed in approximately 25% of breast cancer cases.
Zeinab Ghesmati   +10 more
doaj  

Toxins VapC and PasB from Prokaryotic TA Modules Remain Active in Mammalian Cancer Cells

open access: yesToxins, 2014
Among the great number of addictive modules which have been discovered, only a few have been characterized. However, research concerning the adoption of toxins from these systems shows their great potential as a tool for molecular biology and medicine.
Łukasz Wieteska   +3 more
doaj   +1 more source

Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia

open access: yesToxins, 2018
Moxetumomab pasudotox is a fusion protein of a CD22-targeting antibody and Pseudomonas exotoxin. Minutes of exposure to Moxetumomab achieves similar cell killing than hours of exposure to a novel deimmunized variant against some acute lymphoblastic ...
Fabian Müller   +5 more
doaj   +1 more source

Regulation of PD‐1PD‐L1 Immune Checkpoints by Gut Microbiota Metabolites and Their Clinical Translational Research: A Review

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 7, July 2026.
ABSTRACT Background Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 pathway have revolutionized cancer immunotherapy, yet their clinical benefit is constrained by variable response rates and immune‐related adverse events. Aims This review systematically analyzes the molecular mechanisms by which key gut microbiota‐derived metabolites ...
Xuanyou Fang, Shuai Yuan, Weijian Mai
wiley   +1 more source

Pore-Forming Proteins from Cnidarians and Arachnids as Potential Biotechnological Tools

open access: yesToxins, 2019
Animal venoms are complex mixtures of highly specialized toxic molecules. Cnidarians and arachnids produce pore-forming proteins (PFPs) directed against the plasma membrane of their target cells.
Esperanza Rivera-de-Torre   +4 more
doaj   +1 more source

De Novo Synthesis in Cancer Immunotherapy: Applications and Prospects

open access: yesMedComm, Volume 7, Issue 7, July 2026.
De novo protein design creates novel structures for cancer immunotherapy, integrating rational design principles like modularity and specificity. Leveraging computational tools, it optimizes cytokine engineering, adoptive cellular therapy, and checkpoint regulation to enhance antitumor immunity.
Yang Jin, Yanfeng Wu, Jianhua Luo
wiley   +1 more source

Mouse CD25-specific recombinant immunotoxin

open access: yes
We generated a mouse CD25 (mCD25)-specific recombinant immunotoxin termed anti-mCD25-PE38. Variable regions of a rabbit monoclonal antibody that specifically reacts to mCD25, but not to hCD25, were used to produce anti-mCD25-PE38.
Kobayashi, Kazuto
core   +1 more source

Home - About - Disclaimer - Privacy